Trial Profile

An Open-label Feasibility Trial of Adjunctive L-arginine and Tetrahydrobiopterin Combination in Patients With Treatment Resistant Schizophrenia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arginine (Primary) ; Sapropterin (Primary)
Indications Schizophrenia
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

04 Jan 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2021.
04 Jan 2022 Planned initiation date changed from 14 Aug 2019 to 11 Sep 2019.
04 Jan 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Study was unable to be started due to unavailability of study medication.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com